Spectrum Pharmaceuticals has resubmitted the BLA for eflapegrastim following the remediation of manufacturing deficiencies at a drug substance facility in Korea. In August 2021, Spectrum received a complete response letter (CRL) from the US Food and Drug Administration (FDA) for its long-acting granulocyte-colony stimulating factor (G-CSF) agent Rolontis (eflapegrastim). The letter, which put a hold on Spectrum’s Biologics License Application (BLA) for eflapegrastim, identified manufacturing challenges. But during his firm’s fourth quarter 2021 financial call last week, CEO Tom Riga…